B Movsas

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. ncbi request reprint Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 15:1549-58. 2001
  2. ncbi request reprint Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Radiology 221:327-31. 2001
  3. ncbi request reprint Quality-of-life trials in lung cancer: past achievements and future challenges
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Hematol Oncol Clin North Am 18:161-86. 2004
  4. ncbi request reprint Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 16:90-5, 100; discussion 100-2, 105-6. 2002
  5. ncbi request reprint Radiotherapy patterns of care study in lung carcinoma
    B Movsas
    Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 21:4553-9. 2003
  6. ncbi request reprint Quality of life in oncology trials: a clinical guide
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:235-47. 2003
  7. ncbi request reprint Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 42:43-50. 1998
  8. ncbi request reprint The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1143-9. 1999
  9. ncbi request reprint Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
  10. ncbi request reprint Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT
    L Wang
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 5:29-41. 2004

Collaborators

Detail Information

Publications97

  1. ncbi request reprint Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 15:1549-58. 2001
    ..Future strategies include novel chemotherapy, methods to reduce toxicity, the emerging role of neoadjuvant therapy, and the promise of new biologic agents...
  2. ncbi request reprint Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    Radiology 221:327-31. 2001
    ..To quantify the extent of neuronal cell loss imparted to the brain by means of radiation therapy through the decline of the amino acid derivative N-acetylaspartate (NAA) by using proton (hydrogen 1) magnetic resonance (MR) spectroscopy...
  3. ncbi request reprint Quality-of-life trials in lung cancer: past achievements and future challenges
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Hematol Oncol Clin North Am 18:161-86. 2004
    ..Future studies should focus on incorporating QOL into phase III studies with clear hypotheses that can ultimately lead to clinically meaningful interventions...
  4. ncbi request reprint Role of adjuvant therapy in resected stage II/IIIA non-small-cell lung cancer
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Oncology (Williston Park) 16:90-5, 100; discussion 100-2, 105-6. 2002
    ..Future strategies include novel chemotherapy, methods to reduce toxicity, the emerging role of neoadjuvant therapy, and the promise of new biologic agents...
  5. ncbi request reprint Radiotherapy patterns of care study in lung carcinoma
    B Movsas
    Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 21:4553-9. 2003
    ..For the first time, a lung Patterns of Care Study was conducted to determine the national patterns of radiation (RT) practice in patients treated for nonmetastatic lung cancer in 1998 to 1999...
  6. ncbi request reprint Quality of life in oncology trials: a clinical guide
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:235-47. 2003
    ..The future challenge will be to translate QOL results into clinically meaningful interventions...
  7. ncbi request reprint Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 42:43-50. 1998
    ....
  8. ncbi request reprint The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 45:1143-9. 1999
    ..The purpose of this study is to analyze the impact of age, histology, Karnofsky performance status (KPS), and specific toxicities on the median survival time (MST) and quality-adjusted survival (QTime) for each treatment strategy...
  9. ncbi request reprint Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 89:2018-24. 2000
    ..The purpose of this study was to analyze the extent of hypoxia in prostate carcinoma tumors using the Eppendorf pO(2) microelectrode and correlate this with pretreatment characteristics and prognostic factors...
  10. ncbi request reprint Stereotactic IMRT for prostate cancer: dosimetric impact of multileaf collimator leaf width in the treatment of prostate cancer with IMRT
    L Wang
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 5:29-41. 2004
    ..78). In conclusion, the use of the mMLC for IMRT of the prostate resulted in significant improvement in the DVH parameters of the prostate and critical organs, which may improve the therapeutic ratio...
  11. ncbi request reprint Surgical patterns of care in operable lung carcinoma treated with radiation
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:526-31. 2006
    ..To determine the national surgical practice patterns of care for operable lung cancer patients treated with radiation...
  12. ncbi request reprint Computed tomography-magnetic resonance image fusion: a clinical evaluation of an innovative approach for improved tumor localization in primary central nervous system lesions
    J P Lattanzi
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Radiat Oncol Investig 5:195-205. 1997
    ..The importation of MRI data into three-dimensional treatment planning is therefore crucial to accurate tumor localization. The fusion process simplifies and improves precision of this task...
  13. ncbi request reprint Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Clin Oncol 23:2145-54. 2005
    ..To test the ability of the cytoprotectant, amifostine, to reduce chemoradiotherapy-induced esophagitis and evaluate its influence on quality of life (QOL) and swallowing symptoms...
  14. ncbi request reprint The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 100:538-43. 2004
    ..However, there is little direct evidence that dose escalation has an impact on distant metastasis (DM) or overall mortality (OM). These associations were examined in the current study...
  15. ncbi request reprint A method for repositioning of stereotactic brain patients with the aid of real-time CT image guidance
    K Paskalev
    Department of Radiation Oncology Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Phys Med Biol 50:N201-7. 2005
    ..05 mm, and they were not statistically significant. The random errors (one standard deviation) were from 0.35 mm (lateral) to 0.58 mm (vertical). The average value of the combined 3D difference was 0.75 mm...
  16. doi request reprint Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health Systems, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Thorac Oncol 5:673-9. 2010
    ..Our study assessed consolidation with either gemcitabine alone or with docetaxel after identical chemoradiation as used in Southwest Oncology Group 9504...
  17. ncbi request reprint Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..To determine whether the radiation dose is a determinant of clinical outcome in patients with a lymph node risk of >15% treated using whole pelvic (WP), partial pelvic (PP), or prostate only (PO) fields...
  18. ncbi request reprint To move or not to move: measurements of prostate motion by urethrography using MRI
    D Mah
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 50:947-51. 2001
    ..Sagittal MRI scans were acquired immediately before and after a localization urethrogram to determine the extent of displacement...
  19. ncbi request reprint Outcomes research in cancer clinical trial cooperative groups: the RTOG model
    D W Bruner
    Radiation Therapy Oncology Group, Philadelphia, PA, USA
    Qual Life Res 13:1025-41. 2004
    ....
  20. ncbi request reprint Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 62:342-50. 2005
    ..The purpose of RTOG 97-12 was to determine the maximum tolerated dose (MTD) of thoracic radiation therapy (RT) with concurrent chemotherapy for patients with limited-stage small-cell lung cancer...
  21. ncbi request reprint Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    Int J Radiat Oncol Biol Phys 68:1145-50. 2007
    ..To identify factors significantly influencing accrual to clinical protocols by analyzing radiation Patterns of Care Study (PCS) surveys of 3,047 randomly selected radiotherapy (RT) patients...
  22. doi request reprint ACR appropriateness criteria on nonsurgical treatment for non-small-cell lung cancer: poor performance status or palliative intent
    Kenneth E Rosenzweig
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10065 6007, USA
    J Am Coll Radiol 6:85-95. 2009
    ..Biologic therapies such as erlotinib and bevacizumab have been incorporated into every phase of chemotherapy with good results...
  23. ncbi request reprint Exploring the role of the radioprotector amifostine in locally advanced non-small cell lung cancer: Radiation Therapy Oncology Group trial 98-01
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 12:40-5. 2002
    ....
  24. ncbi request reprint Intracranial fibrosarcoma arising 5 years after chemotherapy alone for glioblastoma multiforme in a child
    J M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, Albert Einstein Medical Center, Philadelphia, PA, USA
    Pediatr Neurosurg 33:257-260. 2000
    ..She remains alive and recurrence-free 7 years following the diagnosis of her second intracranial malignancy...
  25. ncbi request reprint Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer
    D Cvetkovic
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Urology 57:821-5. 2001
    ..The results of our study further support the exploration of antiangiogenesis strategies for the treatment of human prostate cancer...
  26. ncbi request reprint Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..To investigate whether low partial pressure of oxygen (PO2) in prostate cancer (CaP) predicts for biochemical outcome after radiotherapy. We previously reported that hypoxic regions exist in human CaP...
  27. ncbi request reprint Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration
    Maria Werner-Wasik
    Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University Hospital, 111 South 11th Street, Bodine Center, Philadelphia, PA 19107, USA
    Semin Oncol 32:S105-8. 2005
    ..These issues are to be addressed in a randomized phase II trial of amifostine given subcutaneously or via intravenous bolus in non-small cell lung cancer patients undergoing chemoradiation treatment...
  28. ncbi request reprint A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy
    Jian Yue Jin
    Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI, USA
    Radiother Oncol 78:177-84. 2006
    ..To develop and evaluate a technique and procedure of using gated-CT images in combination with PET image to determine the internal target volume (ITV), which could reduce the planning target volume (PTV) with adequate target coverage...
  29. doi request reprint Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
    Int J Radiat Oncol Biol Phys 74:1047-53. 2009
    ..To determine the feasibility, safety, and efficacy of stereotactic body radiation therapy (SBRT), also known as radiosurgery, in patients with head-and-neck cancers...
  30. ncbi request reprint Quantification of incidental dose to potential clinical target volume (CTV) under different stereotactic body radiation therapy (SBRT) techniques for non-small cell lung cancer - tumor motion and using internal target volume (ITV) could improve dose distr
    Jian Yue Jin
    Department of Radiation Oncology, Henry Ford Hospital, 2799 W Grand Boulevard, Detroit, MI 48202, USA
    Radiother Oncol 85:267-76. 2007
    ..This study aimed to quantify the incidental dose to the potential CTV under different SBRT techniques...
  31. ncbi request reprint Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy w
    Maria Werner-Wasik
    Kimmel Cancer Center of Jefferson Medical College, Philadelphia, PA 19107, USA
    Semin Oncol 31:47-51. 2004
    ....
  32. ncbi request reprint A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC)
    Samir H Patel
    Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan 48202, USA
    J Thorac Oncol 2:831-7. 2007
    ..We investigated the toxicity, response rate, and overall survival (OS) with induction carboplatin and vinorelbine followed by concomitant topotecan and ART in patients with locally advanced/unresectable NSCLC...
  33. ncbi request reprint Gender differences in pretreatment quality of life in a prospective lung cancer trial
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Support Oncol 6:33-9. 2008
    ..Understanding the interaction between gender and performance status could lead to better prognosticators and potentially could tailor interventions for specific groups of patients with lung cancer...
  34. doi request reprint Patterns of missing mini mental status exam (MMSE) in radiation therapy oncology group (RTOG) brain cancer trials
    K Bae
    Statistics Department, Radiation Therapy Oncology Group, 1818 Market St Suite 1600, Philadelphia, PA 19103, USA
    J Neurooncol 105:383-95. 2011
    ....
  35. ncbi request reprint Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06
    C B Scott
    Radiation Therapy Oncology Group, Statistical Unit, Philadelphia, PA 19107 2914, USA
    Int J Radiat Oncol Biol Phys 40:51-5. 1998
    ..The purpose of the current analysis was to validate the RPA classes with a new dataset (RTOG 90-06), determine the predictive power of the RPA classes, and establish the usefulness of the database norms for the RPA classes...
  36. doi request reprint Impact of fraction size on lung radiation toxicity: hypofractionation may be beneficial in dose escalation of radiotherapy for lung cancers
    Jin Yue Jin
    Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI 48202, USA
    Int J Radiat Oncol Biol Phys 76:782-8. 2010
    ..To assess how fraction size impacts lung radiation toxicity and therapeutic ratio in treatment of lung cancers...
  37. ncbi request reprint Treatment of stage II non-small cell lung cancer
    Walter J Scott
    Department of Surgical Oncology, Section of Thoracic Surgical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Chest 123:188S-201S. 2003
    ..Superior sulcus tumors are discussed elsewhere in these guidelines...
  38. ncbi request reprint Emotional well-being does not predict survival in head and neck cancer patients: a Radiation Therapy Oncology Group study
    James C Coyne
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer 110:2568-75. 2007
    ..The objective of the current study was to examine whether emotional well-being predicted survival in a large sample of patients with head and neck cancer who were participating in multicenter clinical trials...
  39. doi request reprint Developing a radiation error scoring system to monitor quality control events in a radiation oncology department
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Am Coll Radiol 6:45-50. 2009
    ..The aims of this study were to evaluate the factors contributing to errors in the treatment of cancer patients undergoing radiation therapy and to develop a grading system that allows for the comparison of errors...
  40. ncbi request reprint Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition)
    Walter J Scott
    Fox Chase Cancer Center Suite C 312, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Chest 132:234S-242S. 2007
    ..Adjuvant therapy (both chemotherapy and radiation therapy) and the use of larger fractions of radiotherapy delivered to a smaller area for nonoperative treatment of early stage NSCLC have shown promising results...
  41. pmc I'm so tired: biological and genetic mechanisms of cancer-related fatigue
    Andrea Barsevick
    Cancer Prevention and Control Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
    Qual Life Res 19:1419-27. 2010
    ....
  42. ncbi request reprint A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients
    Robert A Schnoll
    Fox Chase Cancer Center, Philadelphia, Cheltenham, Pennsylvania 19012, USA
    Ann Behav Med 30:1-11. 2005
    ....
  43. ncbi request reprint A phase II study of concurrent carboplatin and paclitaxel and thoracic radiotherapy for completely resected stage II and IIIA non-small cell lung cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Thorac Oncol 2:287-92. 2007
    ..To determine the feasibility of combining concurrent carboplatin/paclitaxel and thoracic radiotherapy (TRT) for completely resected stage II and IIIA non-small cell lung cancer...
  44. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  45. ncbi request reprint Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials
    Andre A Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 24:4177-83. 2006
    ..This study evaluated whether males without partners were disadvantaged for survival in Radiation Therapy Oncology Group (RTOG) head and neck cancer clinical trials...
  46. ncbi request reprint Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma
    Corey J Langer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Thorac Oncol 2:203-9. 2007
    ..6 months in advanced NSCLC (Jagasia et al.; Clinical Cancer Research 7: 68, 2001). A weekly schedule for each agent (versus less frequent doses) limits toxicity and increases the opportunity for radiosensitization...
  47. ncbi request reprint The influence of gender, race, and marital status on survival in lung cancer patients: analysis of Radiation Therapy Oncology Group trials
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    J Thorac Oncol 5:631-9. 2010
    ..A meta-analysis was conducted to determine the influence of gender, race, and marital status on overall survival (OS) in Radiation Therapy Oncology Group nonoperative non-small cell lung cancer trials...
  48. ncbi request reprint Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio
    Alan E Nahum
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:391-401. 2003
    ....
  49. ncbi request reprint A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate
    Robert A Price
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:843-52. 2003
    ..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
  50. ncbi request reprint MRI simulation: effect of gradient distortions on three-dimensional prostate cancer plans
    Dennis Mah
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 53:757-65. 2002
    ..To quantify the dosimetric consequences of external patient contour distortions produced on low-field and high-field MRIs for external beam radiation of prostate cancer...
  51. ncbi request reprint Longitudinal predictors of continued tobacco use among patients diagnosed with cancer
    Robert A Schnoll
    Fox Chase Cancer Center, Psychological and Behavioral Medicine Program, Cheltenham, PA 19012, USA
    Ann Behav Med 25:214-22. 2003
    ..continuous smokers exhibited a significantly lower level of risk perceptions than continuous abstainers. These findings can be useful for the development and evaluation of treatments to promote smoking cessation among cancer patients...
  52. ncbi request reprint Comparing cancer patients who enroll in a smoking cessation program at a comprehensive cancer center with those who decline enrollment
    Robert A Schnoll
    Division of Population Science, Fox Chase Cancer Center, 510 Township Line Road, Cheltenham, Pennsylvania 19012, USA
    Head Neck 26:278-86. 2004
    ..We examined reasons patients provide for declining smoking treatment and compared treatment decliners to enrollees...
  53. ncbi request reprint Characteristics of cancer patients entering a smoking cessation program and correlates of quit motivation: implications for the development of tobacco control programs for cancer patients
    Robert A Schnoll
    Division of Population Science, Fox Chase Cancer Center, 510 Township Line Road, Cheltenham, PA 19012, USA
    Psychooncology 13:346-58. 2004
    ..These findings can help guide the development of smoking cessation interventions for cancer patients...
  54. ncbi request reprint Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  55. ncbi request reprint Correlates of tobacco use among smokers and recent quitters diagnosed with cancer
    Robert A Schnoll
    Psychosocial and Behavioral Medicine Program, Fox Chase Cancer Center, 510 Township Line Road, Cheltenham, PA 19012, USA
    Patient Educ Couns 46:137-45. 2002
    ....
  56. ncbi request reprint Stereotactic IMRT for prostate cancer: setup accuracy of a new stereotactic body localization system
    Lu Wang
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 5:18-28. 2004
    ..A rigid frame system serves as a reliable alignment reference in terms of repositioning patients into the planning position, while skin-based reference showed larger deviations in repositioning patients...
  57. ncbi request reprint Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
    Corey J Langer
    Fox Chase Cancer Center, 333 Cotman AVE, Philadelphia, PA 19111, USA
    Lung Cancer 48:93-102. 2005
    ..ASCO 2000;19:484a; Furuse. JCO 1999;17:2692-9; Zatloukal. ASCO 2002;A-1159]. Data are less secure regarding the role of chemotherapy in stage I and II NSCLC...
  58. ncbi request reprint The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up
    Melvyn Goldberg
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Ann Thorac Surg 79:1174-9. 2005
    ..We reviewed our experience with multimodality therapy for superior sulcus tumors to identify aspects of treatment that impact survival...
  59. ncbi request reprint Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  60. ncbi request reprint Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04
    K J Murray
    Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Int J Radiat Oncol Biol Phys 48:59-64. 2000
    ..This study examines the importance of the MMSE in predicting outcome in a group of patients treated with an accelerated fractionation regimen of 30 Gy in 10 daily fractions in 2 weeks...
  61. ncbi request reprint Optimum beam angles for the conformal treatment of lung cancer: a CT simulation study
    I J Das
    Department of Radiation Oncology, University of Pennsylvania, 3400 Spruce St, 2 Donner Building, Philadelphia, PA 19104, USA
    Int J Cancer 90:359-65. 2000
    ..A CT simulator is ideally suited for simulation of lung cancer to maximize the clearance from the spinal cord and minimize the additional lung volume irradiated. Int. J. Cancer (Radiat. Oncol. Invest.) 90, 359-365 (2000)...
  62. ncbi request reprint Can costs be measured and predicted by modeling within a cooperative clinical trials group? Economic methodologic pilot studies of the radiation therapy oncology group (RTOG) studies 90-03 and 91-04
    J B Owen
    Radiation Therapy Oncology Group, American College of Radiology, 1101 Market Street, Suite 1400, Philadelphia, PA 19107, USA
    Int J Radiat Oncol Biol Phys 49:633-9. 2001
    ....
  63. ncbi request reprint Hypoxia in human prostate carcinoma: an Eppendorf PO2 study
    B Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:458-61. 2001
    ..More patients will be accrued to this study to ultimately correlate the oxygenation status in prostate carcinoma tumors with treatment outcome...
  64. ncbi request reprint 2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions
    Jian Yue Jin
    Department of Radiation Oncology, Henry Ford Hospital, 2799 W Grand Boulevard, Detroit, Michigan 48202, USA
    Med Phys 33:4557-66. 2006
    ..The overall uncertainty of the mask system was +/-4 mm, and the reproducibility was +/-2.9 mm in terms of 95% CI. The study demonstrated that the image guidance system provides accurate and precise target positioning...
  65. doi request reprint Radiation pulmonary toxicity: from mechanisms to management
    Paul R Graves
    Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA, USA
    Semin Radiat Oncol 20:201-7. 2010
    ....
  66. ncbi request reprint Effects of prescription depth, cylinder size, treatment length, tip space, and curved end on doses in high-dose-rate vaginal brachytherapy
    Shidong Li
    Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Int J Radiat Oncol Biol Phys 67:1268-77. 2007
    ..To determine the effects of the prescription depth, cylinder size, treatment length, tip space, and curved end on high-dose-rate vaginal brachytherapy (HDR-VBT) of endometrial cancer...
  67. ncbi request reprint Metastatic meningioma to the lung with multiple pleural metastases
    J M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Am J Clin Oncol 24:579-82. 2001
    ..We report an interesting case of a malignant meningioma that invaded through the skull in the frontal sinus that later metastasized to the left lung with multiple pulmonary and pleural nodules...
  68. ncbi request reprint Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme
    C J Langer
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 51:113-9. 2001
    ..The Radiation Therapy Oncology Group (RTOG) therefore mounted a Phase II study to determine the feasibility and efficacy of conventional EBRT and concurrent weekly TAX at its MTD...
  69. ncbi request reprint Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine
    Loren K Mell
    University of California San Diego, Department of Radiation Oncology, La Jolla, California, USA
    Expert Opin Drug Metab Toxicol 4:1341-50. 2008
    ..Amifostine is a cytoprotector that can reduce toxicity and potentially improve the therapeutic ratio of radiotherapy...
  70. pmc Analysis of outcomes in radiation oncology: an integrated computational platform
    Dezhi Liu
    Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA
    Med Phys 36:1680-9. 2009
    ..In addition the database is web-based and accessible by multiple users, facilitating its convenient application and use...
  71. doi request reprint Can physicians accurately predict survival time in patients with metastatic cancer? Analysis of RTOG 97-14
    William F Hartsell
    Department of Radiation Oncology, Advocate Good Samaritan Cancer Center, Downers Grove, Illinois 60515, USA
    J Palliat Med 11:723-8. 2008
    ..To determine if physician prediction of survival duration (PSD) is accurate for patients with metastatic breast or prostate cancer...
  72. doi request reprint Clinical, dosimetric, and radiographic correlation of radiation injury involving the brainstem and the medial temporal lobes following stereotactic radiotherapy for neoplasms of central skull base
    Stefano Schipani
    Department of Radiation Oncology, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI, 48202, USA
    J Neurooncol 98:177-84. 2010
    ..Brainstem lesions occurred earlier than temporal lobe RI. The majority of the RI lesions, not mixed with the tumor in this study, showed radiographic and clinical improvement with steroid and symptomatic treatments...
  73. ncbi request reprint Recent advances and dilemmas in the radiotherapeutic management of locally advanced non-small cell lung cancer
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Methods Mol Med 75:489-505. 2003
  74. pmc Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801
    Benjamin Movsas
    Department of Radiation Oncology, Henry Ford Hospital, Detroit, MI 48202, USA
    J Clin Oncol 27:5816-22. 2009
    ..To determine the added value of quality of life (QOL) as a prognostic factor for overall survival (OS) in patients with locally advanced non-small-cell lung cancer (NSCLC) treated on Radiation Therapy Oncology Group RTOG-9801...
  75. ncbi request reprint Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
    Int J Radiat Oncol Biol Phys 70:353-60. 2008
    ....
  76. ncbi request reprint The role of radiation therapy and chemotherapy in the management of airway tumors other than small-cell carcinoma and non-small-cell carcinoma
    Joseph M Kaminski
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Chest Surg Clin N Am 13:149-67. 2003
    ..In the future, patients might receive individually tailored therapy based upon unique molecular-genetic alterations of the tumor...
  77. ncbi request reprint Quality-of-life outcomes in oncology
    Farzan Siddiqui
    Department of Radiation Oncology, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, and Department of Radiation Oncology, Boston University Medical Center, MA, USA
    Hematol Oncol Clin North Am 20:165-85. 2006
    ..The current challenge is to understand better the clinical relevance of QOL research in oncology. QOL studies should focus on phase III trials with clear hypotheses that can lead to clinically meaningful interventions...
  78. ncbi request reprint Radiation esophagitis: Predictive factors and preventive strategies
    Jeffrey Bradley
    Department of Radiation Oncology, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Semin Radiat Oncol 14:280-6. 2004
    ..Preventive strategies to minimize this toxicity also are explored. Overall, this article reviews the current understanding of radiation toxicity for the esophagus...
  79. ncbi request reprint Prostate cancer gene therapy clinical trials
    Svend O Freytag
    Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Mol Ther 15:1042-52. 2007
    ..Much work lies ahead. Nevertheless, for the time being, these studies provide hope that gene therapy may someday earn a place in the management of prostate cancer...
  80. ncbi request reprint Comparison of similarity measures for rigid-body CT/Dual X-ray image registrations
    Jinkoo Kim
    Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
    Technol Cancer Res Treat 6:337-46. 2007
    ..In the clinical applications, registrations starting with the mutual information followed by the gradient difference may provide the best accuracy and the most robustness...
  81. ncbi request reprint Daily target localization for prostate patients based on 3D image correlation
    K Paskalev
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Phys Med Biol 49:931-9. 2004
    ..The impact of image noise on the performance of the algorithm has been tested. The results show that the algorithm accurately adjusts for target positional changes even with Gaussian noise levels as high as 20% inserted...
  82. doi request reprint How often are previously undetected radiographic abnormalities detected at the time of CT simulation for breast cancer patients?
    Sishir Rao
    Department of Radiation Oncology, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, USA
    Am J Clin Oncol 33:262-4. 2010
    ..The purpose of this analysis was to determine the percentage of cases in which a previously undetected radiographic finding was found on review of CT simulation images by diagnostic radiology...
  83. ncbi request reprint Processes of change related to smoking behavior among cancer patients
    Robert A Schnoll
    Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer Pract 10:11-9. 2002
    ..The relationship between medical variables and processes of change was also explored...
  84. ncbi request reprint Imaging response in malignant glioma, RTOG 90-06
    Robert A Lustig
    Hospital of the University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA 19104, USA
    Am J Clin Oncol 30:32-7. 2007
    ..This study compared patients treated with hyperfractionated radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to standard fractionation and BCNU...
  85. ncbi request reprint Dose delivered from Varian's CBCT to patients receiving IMRT for prostate cancer
    Ning Wen
    Henry Ford Health System, Detroit, MI, USA
    Phys Med Biol 52:2267-76. 2007
    ..The surface and in vivo doses were also measured for phantoms at the central-axis setup. The difference was less than approximately 12% to the table-drop setup...
  86. ncbi request reprint Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study
    David S Ettinger
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    J Clin Oncol 23:4991-8. 2005
    ....
  87. ncbi request reprint Will future progress in non-small-cell lung cancer be step by step... or by leaps and bounds?
    Benjamin Movsas
    J Clin Oncol 23:5859-61. 2005
  88. ncbi request reprint Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis
    Benjamin Movsas
    Radiation Oncology, Henry Ford Health System, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 65:830-5. 2006
    ..The purpose of this analysis was to assess the impact of pretreatment factors on quality of life (QOL) in cancer patients...
  89. ncbi request reprint A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04)
    Jeffrey D Bradley
    Radiation Oncology Center, Washington University Medical Center, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 52:1173-9. 2002
    ..Based on these data, the Radiation Therapy Oncology Group (RTOG) initiated a Phase III trial to test the efficacy of beta-interferon in poor-risk patients with Stages IIIA and IIIB non-small-cell lung carcinoma...
  90. ncbi request reprint Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer
    Benjamin Movsas
    Henry Ford Health System, Radiation Oncology, Detroit, MI 48202, USA
    Am J Clin Oncol 29:435-41. 2006
    ..The purpose of this phase II study was to prospectively determine the efficacy of preoperative chemoradiation with a hyperfractionated (Hfx) RT boost to 61.8 Gy in locally advanced rectal cancer...
  91. ncbi request reprint Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31
    Miljenko V Pilepich
    University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    Int J Radiat Oncol Biol Phys 61:1285-90. 2005
    ..Radiation Therapy Oncology Group protocol 85-31 was designed to evaluate the effectiveness of adjuvant androgen suppression, using goserelin, in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy (RT)...
  92. doi request reprint Examining margin reduction and its impact on dose distribution for prostate cancer patients undergoing daily cone-beam computed tomography
    Rabih Hammoud
    Josephine Ford Downriver Center for Oncology, Henry Ford Health System, Brownstown, MI, USA
    Int J Radiat Oncol Biol Phys 71:265-73. 2008
    ..To examine the dosimetric impact of margin reduction and quantify residual error after three-dimensional (3D) image registration using daily cone-beam computed tomography (CBCT) for prostate cancer patients...
  93. ncbi request reprint Imaging to optimally stage lung cancer: conventional modalities and PET/CT
    Mylene T Truong
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Am Coll Radiol 1:957-64. 2004
    ..This article reviews current recommendations regarding the staging of patients with NSCLC and addresses the role of PET/CT...
  94. doi request reprint Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118
    Benjamin W Corn
    Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel
    Int J Radiat Oncol Biol Phys 71:71-8. 2008
    ..This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes...
  95. ncbi request reprint Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis
    Loren K Mell
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL, USA
    Int J Radiat Oncol Biol Phys 68:111-8. 2007
    ..Studies with sufficient statistical power to address this question are lacking...
  96. doi request reprint A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118)
    Jonathan P S Knisely
    Department of Therapeutic Radiology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT 06520 8040, USA
    Int J Radiat Oncol Biol Phys 71:79-86. 2008
    ..To compare whole-brain radiation therapy (WBRT) with WBRT combined with thalidomide for patients with brain metastases not amenable to resection or radiosurgery...
  97. ncbi request reprint Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks
    Deborah Watkins Bruner
    Radiation Therapy Oncology Group, University of Pennsylvania, School of Nursing American College of Radiology Imaging Network, Philadelphia, PA 19104 6096, USA upenn edu
    J Clin Oncol 25:5051-7. 2007
    ..The objective of this report is to provide a historical overview of and the issues and challenges inherent in the incorporation of patient-reported outcomes (PROs) into multinational cancer clinical trials in the cancer cooperative groups...